C2N Diagnostics has established partnerships with six new clinical reference laboratories and distributors, extending access to its PrecivityAD2™ blood test across over seven additional countries. The new collaborators include Accuserv Diagnostic Center (Philippines), Archerfish Precision Diagnostics (Singapore and Southeast Asia), Codex Genetics (Hong Kong), Dr. Dangs Lab (India), Medical Link (Israel), and Milenia Labs (Costa Rica and Mexico).
According to the company, this expansion targets regions with limited PET imaging infrastructure and increasing healthcare demands. The PrecivityAD2™ blood test offers a non-invasive method to assess amyloid pathology—a key indicator in Alzheimer’s disease—for individuals with cognitive concerns.
C2N already maintains collaborations with major global laboratories such as Grupo Fleury, Healius, Mayo Clinic Laboratories, and Unilabs, and holds a research partnership with Mediford.
This strategic initiative is intended to enhance early and accurate Alzheimer’s disease detection by making clinically validated, high-accuracy diagnostics more accessible to physicians and patients worldwide.
